Reply to 'Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?'
Eur J Heart Fail
.
2022 Dec;24(12):2393-2394.
doi: 10.1002/ejhf.2734.
Epub 2022 Nov 17.
Authors
Alberto Domínguez-Rodríguez
1
2
,
Daniel Hernandez-Vaquero
3
4
,
Òscar Miró
5
Affiliations
1
Department of Cardiology, Hospital Universitario de Canarias, Universidad Europea de Canarias, Tenerife, Spain.
2
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
3
Cardiac Surgery Department, Central University Hospital of Asturias, Oviedo, Spain.
4
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
5
Emergency Department, Hospital Clinic, Institutd' Investigación Biomèdica August Pi iSunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
PMID:
36377097
DOI:
10.1002/ejhf.2734
No abstract available
Publication types
Letter
Comment
MeSH terms
Acute Disease
Heart Failure* / complications
Heart Failure* / drug therapy
Humans
Morphine Derivatives
Pulmonary Edema* / drug therapy
Pulmonary Edema* / etiology
Substances
Morphine Derivatives